JP2011509956A - イミダゾリキノリン誘導体を用いた大腸疾病の治療又は結腸直腸癌腫の予防 - Google Patents

イミダゾリキノリン誘導体を用いた大腸疾病の治療又は結腸直腸癌腫の予防 Download PDF

Info

Publication number
JP2011509956A
JP2011509956A JP2010542534A JP2010542534A JP2011509956A JP 2011509956 A JP2011509956 A JP 2011509956A JP 2010542534 A JP2010542534 A JP 2010542534A JP 2010542534 A JP2010542534 A JP 2010542534A JP 2011509956 A JP2011509956 A JP 2011509956A
Authority
JP
Japan
Prior art keywords
imidazoliquinoline
colorectal
treatment
imiquimod
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010542534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509956A5 (enExample
Inventor
マウス ヨアヒム
スツェレニィ イストヴァン
ペツォルト ウルズラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda AB
Original Assignee
Meda AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011509956(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda AB filed Critical Meda AB
Publication of JP2011509956A publication Critical patent/JP2011509956A/ja
Publication of JP2011509956A5 publication Critical patent/JP2011509956A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2010542534A 2008-01-15 2008-12-23 イミダゾリキノリン誘導体を用いた大腸疾病の治療又は結腸直腸癌腫の予防 Pending JP2011509956A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US645908P 2008-01-15 2008-01-15
PCT/EP2008/011088 WO2009089900A1 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Publications (2)

Publication Number Publication Date
JP2011509956A true JP2011509956A (ja) 2011-03-31
JP2011509956A5 JP2011509956A5 (enExample) 2013-12-12

Family

ID=40419193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010542534A Pending JP2011509956A (ja) 2008-01-15 2008-12-23 イミダゾリキノリン誘導体を用いた大腸疾病の治療又は結腸直腸癌腫の予防

Country Status (15)

Country Link
US (1) US8008319B2 (enExample)
EP (1) EP2237780A1 (enExample)
JP (1) JP2011509956A (enExample)
CN (1) CN101909624A (enExample)
AU (1) AU2008347400B2 (enExample)
BR (1) BRPI0822002A2 (enExample)
CA (1) CA2708559C (enExample)
EA (1) EA018579B1 (enExample)
GE (1) GEP20125605B (enExample)
IL (1) IL205819A (enExample)
MX (1) MX2010007699A (enExample)
NZ (1) NZ586161A (enExample)
UA (1) UA101339C2 (enExample)
WO (1) WO2009089900A1 (enExample)
ZA (1) ZA201003906B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
SG11201605296SA (en) 2014-01-10 2016-07-28 Birdie Biopharmaceuticals Inc Compounds and compositions for treating her2 positive tumors
DK3166976T3 (da) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc Anti-pd-l1-kombinationer til behandling af tumorer
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) * 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078547C1 (ru) * 1995-11-28 1997-05-10 Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ Способ лечения полипоза желудка и двенадцатиперстной кишки
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
ATE400573T1 (de) * 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1h-imidazochinolinderivate als proteinkinaseinhibitoren

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013027165; ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．５２, 1992, ｐ．３５２８-３５３３ *
JPN6013027166; ＤＩＳＥＡＳＥＳ　ＯＦ　ＴＨＥ　ＣＯＬＯＮ＆ＲＥＣＴＵＭ Ｖｏｌ．５１，Ｎｏ．１, 200711, ｐ．２-９ *
JPN6013027167; Ｎ　Ｅｎｇｌ　Ｊ　Ｍｅｄ Ｖｏｌ．３４７，Ｎｏ．５, 2002, ｐ．３７４ *
JPN6013027168; Ｐｒｏｃｅｅｄ．Ｉｎｔ'ｌ．Ｓｙｍｐ．Ｃｏｎｔｒｏｌ．Ｒｅｌ．Ｂｉｏａｃｔ．Ｍａｔｅｒ．１９９７年，Ｎ２４，ｐ．３３７-３３８ *

Also Published As

Publication number Publication date
AU2008347400B2 (en) 2014-12-11
US8008319B2 (en) 2011-08-30
US20090182005A1 (en) 2009-07-16
CA2708559C (en) 2015-10-06
CA2708559A1 (en) 2009-07-23
IL205819A0 (en) 2010-11-30
MX2010007699A (es) 2010-08-04
NZ586161A (en) 2012-05-25
IL205819A (en) 2013-02-28
GEP20125605B (en) 2012-08-10
WO2009089900A1 (en) 2009-07-23
ZA201003906B (en) 2011-03-30
EA201001164A1 (ru) 2010-12-30
EA018579B1 (ru) 2013-09-30
BRPI0822002A2 (pt) 2015-10-13
AU2008347400A1 (en) 2009-07-23
EP2237780A1 (en) 2010-10-13
UA101339C2 (ru) 2013-03-25
CN101909624A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
JP2011509956A (ja) イミダゾリキノリン誘導体を用いた大腸疾病の治療又は結腸直腸癌腫の予防
Lin et al. QingBai decoction regulates intestinal permeability of dextran sulphate sodium‐induced colitis through the modulation of notch and NF‐κB signalling
Du et al. cGAS-STING signaling in cancer immunity and immunotherapy
Gupta et al. Viral and nonviral uses of imiquimod: a review
Wang et al. 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway
El-Magd et al. Trehalose enhances the antitumor potential of methotrexate against mice bearing Ehrlich ascites carcinoma
Yoshiji et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression
Goebell et al. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial
Adhauliya et al. Autophagy: A boon or bane in oral cancer
JP2012517427A5 (enExample)
Guo et al. Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis
Wang et al. Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways
WO2006084197A2 (en) Nitroxides for use in treating or preventing neoplastic disease
Lin et al. Shrimp anti-lipopolysaccharide factor peptide enhances the antitumor activity of cisplatin in vitro and inhibits HeLa cells growth in nude mice
Sanz-Motilva et al. Non-steroidal anti-inflammatory drugs and melanoma
WO2014039742A1 (en) Combination treatments for melanoma
BR112015005284B1 (pt) Combinação de compostos derivados do ácido gálico, composição farmacêutica compreendendo a referida combinação e seus usos no tratamento de câncer
Gkoulioni et al. The efficacy of imiquimod on dysplastic lesions of the oral mucosa: an experimental model
Liauα et al. Royal Family’s Cancer Diagnoses Offer a Supreme Authority to Rectify Cancer Therapies to Save Cancer Patients
HK1151220A (en) Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
Kim et al. 15-Lipoxygenase-1 induced by interleukin-4 mediates apoptosis in oral cavity cancer cells
CN114569604A (zh) 一种下调衰老相关分泌表型的抗衰老组合药物及其应用
WO2022000708A1 (zh) 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用
CN110538172A (zh) 铁死亡抑制剂在制备治疗金诺芬肝毒性的药物中的应用
WO2014172857A1 (zh) 阿可拉定在制备用于治疗原发性肝癌的药物中的用途

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20111031

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20111031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111108

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20111108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130903

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130910

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131210